Montelukast Sodium
Product Images NDC 60723-004

5 FDA label images from Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 60723-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

4 mg-30s Bottle Label (4mg 30s)

4 mg-30s Bottle Label (4mg 30s)
Montelukast Sodium Chewable Tablets 4 mg label displaying product strength and pediatric use for ages 2-5 years. The label includes dosage information, warnings about phenylketonurics, storage instructions, manufacturer Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd., and a 30-tablet count. Also visible is the NDC number and barcode.*
FDA Label Image

5 mg-30s Bottle Label (5mg 30s)

5 mg-30s Bottle Label (5mg 30s)
Label for Montelukast Sodium Chewable Tablets, 5 mg, intended for pediatric patients aged 6-14 years. The package contains 30 chewable tablets. It includes dosing information, storage instructions, and a warning for phenylketonurics about phenylalanine content. Manufactured by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd., located in Zhejiang, China.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing change in height (cm) over weeks on treatment for Montelukast Sodium 5 mg, Beclomethasone 336 mcg, and placebo groups. The x-axis represents weeks on treatment from -19 to 56, and the y-axis shows height change from -3 to 7 cm. Three distinct trend lines represent growth changes for each group over time.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting the mean percent change from baseline over weeks in treatment for Montelukast Sodium compared to placebo. The x-axis represents weeks in treatment, including a washout period, while the y-axis shows mean percent change. Montelukast Sodium shows a higher increase over weeks with a decline during washout, whereas placebo shows a smaller, steady increase.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Montelukast Sodium, showing its distinct molecular framework including chlorine, sulfur, and sodium carboxylate groups in a complex aromatic and aliphatic configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.